Background: CVS (cyclic vomiting syndrome) is a functional disorder that may occur in any age group of patients. In the past the disorder was considered to be fairly uncommon of unknown etiology. Treatment has generally been based on anecdotal reports.
Methods: Literature review was performed based on internet/Medline search as of April 2006.
Results: CVS is much more common than previously thought, especially in adults and is commonly associated with migraine headaches and sharing many of its characteristic features. Genetic association with mitochondrial DNA has been recognized with CVS. Prompt diagnosis is essential in order to prevent the significant morbidity associated with CVS. It is mandatory to rule out certain life-threatening disorders that can mimic CVS. Treatment options are based on the particular phase of the syndrome in which a patient is in and carried out in a systematic manner.
Conclusion: Expert consensus is that CVS is a distinct disorder and is a part of the migraine spectrum (migraine headaches, CVS, and abdominal migraines). Once patients are properly diagnosed, treatment is highly effective. Because of renewed interest in CVS since the 1990's, many more patients in all age groups are being recognized who suffer from this disabling disorder. An increase in basic science and clinical research in CVS will hopefully lead to better patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1572-0241.2007.01549.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Medicare Coverage of Overactive Bladder Medications in the United States.
Urogynecology (Phila)
December 2024
From the Urogynecology and Reconstructive Pelvic Surgery, MedStar Washington Hospital Center/Georgetown University, Washington, DC.
Importance: Strong evidence demonstrates long-term cognitive decline associated with anticholinergics. While prevalent among older populations, medical management of overactive bladder (OAB) is dictated by insurance coverage rather than medical provider and patient preferences.
Objective: The aim of this study was to assess Medicare insurance plan coverage for select OAB medications and evaluate coverage of preferred medications to medications with a greater risk of cognitive dysfunction.
Public Health.
Alzheimers Dement
December 2024
NIA-Layton Aging & Alzheimer's Disease Research Center, Portland, OR, USA.
Background: Nutrient biomarkers (NBs) may serve as more accurate and precise indicators of dietary intake, particularly in older adults who often have subtle episodic memory recall and digestive/microbiome issues that alter the nutritional substrate readily available to the brain. NBs also allow insight into modes of action and metabolic changes that are actionable targets for modification through nutritional means in hopes of disease prevention and treatment. Prior to broad investment and deployment, the pre-analytical and intra-individual temporal variation over time should be documented to design and interpret clinical and epidemiological studies properly.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Background: Alzheimer's disease (AD) is a multifaceted condition associated with various brain pathologies, necessitating diverse biomarkers for precise prognosis, diagnosis, clinical management, and therapeutic development/evaluation. The integration of multiple biomarkers into a single test can enhance efficiency, reduce analytical errors, and save on specimen volume. Alamar Biosciences recently introduced the NULISAseq CNS disease panel, a multiplex NUcleic acid-linked Immuno-Sandwich Assay (NULISA) targeting ∼120 analytes.
View Article and Find Full Text PDFBackground: The rapidly growing pipeline of target-specific Alzheimer's Disease (AD) therapeutic candidates requires accompanying tests that can identify patients likely to have a beneficial response. The growing importance of multiple pathologies in determining AD progression and treatment response underscores this need. Our work focuses on establishing analytical capability to expand detectable forms of major protein drug targets for AD: Tau, amyloid beta (Ab) and a-Synuclein (aS) proteoforms as potential personalized molecular signatures.
View Article and Find Full Text PDFValidation of a mail-in delayed semen analysis protocol developed for home collection.
F S Rep
December 2024
Quest Diagnostics, Secaucus, New Jersey.
Objective: To validate a mail-in delayed semen analysis service using deidentified remnant samples from a US fertility clinic.
Design: Double-blinded prospective validation of screening/diagnostic test.
Setting: Fertility clinic and clinical reference laboratory.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!